Drug · Other
Goserelin
CI-DRUG-00000688Explore in graph →CHEMBL1201247 Approved
Regulatory
Approvals (13)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-11
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260914-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| US FDA | — | Efficacy supplement 1998-07-27 (see label) | approved | Jul 27, 1998 | openfda |
| US FDA | — | Efficacy supplement 1998-07-27 (see label) | approved | Jul 27, 1998 | openfda |
| US FDA | — | Efficacy supplement 1998-04-09 (see label) | approved | Apr 9, 1998 | openfda |
| US FDA | — | Efficacy supplement 1997-06-27 (see label) | approved | Jun 27, 1997 | openfda |
| US |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 15 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 37 | 19 | 71 | 189 | 13 | CA, US | Dec 29, 1989 | 1987-05 |
| Malignant Prostate Neoplasm | Approved | Phase 4 | 17 | 7 | 37 | 93 | 4 | US | Dec 29, 1989 | 1987-05 |
| Malignant Breast Neoplasm | Approved | Phase 4 | 12 | 8 | 29 | 75 | 1 | US | Dec 29, 1989 | 1987-09 |
| Malignant Uterine Corpus Neoplasm | Phase4 | Phase 4 | 0 | 0 | 0 | 1 |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (194)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer(Adjuvant WIDER) | recruiting | Phase 3 | 1,400 | Novartis PharmaceuticalsINDUSTRY | 16 | Sep 29, 2026 | clinicaltrials |
| NCT01723774 | PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | active not recruiting |